Dominick Colangelo, 61 President and Chief Executive Officer, Vericel Director Since: 2013 Other Current Public Company Directorships: Vericel Board committee(s): Trevi Therapeutics, Inc. None Key Experience and Qualifications CEO/GM: Mr. Colangelo has more than 20 years of executive management experience in the biopharmaceutical industry. For the past 11 years he has served as President and CEO of Vericel, spearheading the acquisition of MACI and Epicel and leading the Company through an extended period of significant revenue and market growth. Mr. Colangelo also served for more than a decade in senior leadership positions at Eli Lilly and Company. Finance: Mr. Colangelo possesses a significant accounting and finance background, which has been developed through education, strategy and business development roles, as well as his service on the audit committee of the board of directors of Trevi Therapeutics. Marketing/Sales: Extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas Business Development: Experience gained through a variety of executive positions in product development, pharmaceutical operations and corporate development Professional Highlights President and Chief Executive Officer and a member of the Board of Directors of Vericel (2013-present) Director of Strategy and Business Development for Eli Lilly s Diabetes Product Group and founding Managing Director of Lilly Ventures at Eli Lilly and Company Other Leadership Positions and Experience Member of the board of directors of Trevi Therapeutics, Inc., a publicly-traded clinical stage biopharmaceutical company focused on the development and commercialization of treatments for chronic cough conditions. Mr. Colangelo is a member of both the audit and compensation committees of the Trevi Therapeutics board. Education B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo J.D., with honors, from the Duke University School of Law